Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Shweta Singh(CytomX Therapeutics (United States)), Jennifer Richardson(Interdisciplinary Dental Education Academy), Andrew Jang(CytomX Therapeutics (United States)), Amy DuPage(CytomX Therapeutics (United States)), Stephen J. Moore(CytomX Therapeutics (United States)), Michael Krimm(CytomX Therapeutics (United States)), Laura Serwer(CytomX Therapeutics (United States)), Matthew M. Ravn(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Shanti Duvur(CytomX Therapeutics (United States)), Jason Sagert(CytomX Therapeutics (United States)), Yingchun Li(AbbVie (United States)), Leyu Wang(AbbVie (United States)), Ken Wong(CytomX Therapeutics (United States)), Susan E. Morgan-Lappe(Abbott Fund), Marcia Belvin(CytomX Therapeutics (United States)), Yuanhui Huang(Sinovac Biotech), W. Michael Kavanaugh(CytomX Therapeutics (United States)), Siew Schleyer(CytomX Therapeutics (United States)), Shouchun Liu(Lanzhou University of Technology), Kristi Elkins, Rob Leanna(AbbVie (United States)), Shawn Jeffries(AbbVie (United States)), Sarah Patrick(CytomX Therapeutics (United States)), Kimberly Tipton(CytomX Therapeutics (United States)), Sridhar Viswanathan(CytomX Therapeutics (United States)), Eric Ureno(CytomX Therapeutics (United States)), Luc Desnoyers(Genentech), Jonathan Terrett, Adam M. Miller(Cornell University), Claus Krebber(CytomX Therapeutics (United States)), Olga Vasiljeva(Jožef Stefan Institute), Ilaria Badagnani(AbbVie (United States)), Tracy Henriques(AbbVie (United States)), Niharika Chauhan(AbbVie (United States))
Cited by 0
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
The CREB Coactivator TORC2 Functions as a Calcium- and cAMP-Sensitive Coincidence Detector
|Cell|2004|660
Integrin cytoplasmic domain-binding proteins
|Journal of Cell Science|2000|571